In a welcome move, Dynavax Technologies saw its Relative Strength Rating improve from 67 to 71 on Tuesday.
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks typically have an 80 or higher RS Rating in the early stages of their moves. See if Dynavax Technologies can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
Dynavax Technologies is trying to complete a cup with handle with a 13.89 entry. See if the stock can clear the breakout price in heavy trading.
Dynavax Technologies reported 20% earnings growth in the latest quarterly report. Revenue increased 16%.
Dynavax Technologies holds the No. 34 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
